State promulgated the "second five" plan, the "biomedical" expanded to "biological", to include bio-medicine,digital thermometer bio-agriculture, bio-energy, bio-environmental protection and other fields, this first study the bio-pharmaceutical industry.
Policies to help biomedical spring growth.
According to industry experts, means the application of biotechnology drugs genetic engineering, protein engineering, clinical thermometer antibody engineering and cell engineering technology, manufacturing for the treatment, prevention and diagnosis of the drug, including therapeutic peptides, proteins, hormones, enzymes, antibodies, cytokines, vaccines,ear thermometer soluble receptors, and nucleic acid drugs.
"Species from the global distribution of biotech drugs, the U.S. accounted for 63% of global share, followed by Europe 25%, digital blood pressure monitor Japan 7%, a very small share of China", China Pharmaceutical University, said Professor Tan Shuhua. So, in the field of biotech drugs around the world, China can only be regarded as a minor seedlings. However, from the current introduction of the "second Five-Year" plan and the upcoming introduction of the policy, countries are interested in tree seedlings will develop into a towering tree.
According to the China Center for Pharmaceutical Science and Technology Achievements, director Rui Guozhong, the "new medical reform from a macro policy of full implementation of the expanded version based medicine, the new GMP (pharmaceutical production management standard), 863 biomedicine, science and technology projects of major new drug, to refine the industry "major infectious diseases special", "Drug Registration", "New Medical Device Regulations," "Chinese medicine injections of 689 new technical standards" and other policies, including bio-medical support around the policy, introduced during the year are expected. " The good policy "is not only more vigorous, and concentrated, to reconstruct the chain of China's biomedical industry."
Accordingly, Rui Guozhong predicts that by 2020 China's biomedical industry will reach 4 trillion yuan in size, more than Japan and Europe to become the world's second largest pharmaceutical market, China's global position in the biopharmaceutical industry rising.
Vaccine related companies, a lot of spectacle.
Subject to space limitations, this paper focuses only on the analysis of bio-pharmaceutical industry sub-sectors in the vaccine.
From the scale point of view, the vaccine market, only about 1.7% of pharmaceutical market is a very small sub-sectors. But the industry is the next most promising sub-sectors. According to a survey PharmaLive's latest report: in 2012, the global vaccine market is expected to reach 34 billion U.S. dollars. And in the next 5 years, will exceed the pace of development agents, to achieve an annual growth rate of 14%.
Development of the vaccine industry is also very large. First of all, it is because of the larger population base; addition, our population is very low vaccination rates to influenza vaccine, for example, vaccination of susceptible populations less than 2%, at a very low level, while the European and American countries universal vaccination rate reached 20% to 30%. At this stage, the size of the vaccine market in China is about 50 billion yuan, an annual growth rate remained at 15%, 2012, the size of China's vaccine market will reach 120 billion yuan. Taking into account the "second five" plan to pay special attention to the vaccine industry, can be predicted that the vaccine industry will be greater and faster development.
A human vaccine stock market listed companies are: Tiantan Biological, Hualan Biological, intellectual flying creatures, Liaoning Cheng Kung University, Changchun High-tech, Watson biology.
Among these, the Temple of the field of biotechnology as a vaccine for the national team, backed by China National Biotec Group, is the vaccine market, "Big Brother." However, the Tiantan Biological product line focused on a class by the state pay for the vaccine market, lower gross profit margin.
Vaccines can be described as the field of vaccine upstart Hualan Biological honors classes.
Data, Hualan Biological Engineering since 2001, net profit for nine consecutive years to maintain positive growth. Originally based on the blood products Hualan objects, the first time H1N1 vaccine will be in the field of the incident Daxian limelight, in January of this year alone by the state purchasing and storage of the H1N1 vaccine reached 12.25 million.
In addition to the Temple of Heaven biological, the rest of the company's product line several more concentrated in individual pay for the two types of vaccine market, the price is high, and therefore, gross profit margin is much higher than the Temple of Heaven creatures.
In addition, investment securities specifically mentioned in the Chongqing Beer, that "changes with the company charter, Jia Chen organism may be stripped from the parent company and basic elimination of uncertainty", so that is also classified as vaccine Chongqing Brewery class biomedical enterprise. CIC Securities believes that the future is to verify that the vaccine will be 1 year clinical results of the most important time, will also be the best time to invest. "We are optimistic about the therapeutic vaccine in the space, the next 10 years, this area could become the most exciting areas of the pharmaceutical industry, there will be a large number of blockbuster products. Chongqing Jia Chen biological treatment of hepatitis B vaccine, will be in this area the important species. "